{
    "info": {
        "nct_id": "NCT06287463",
        "official_title": "A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Antitumor Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway",
        "inclusion_criteria": "General Inclusion Criteria ModA Part 1 and 2:\n\n* Able to take oral medication\n* If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements\n* Adequate organ function and electrolytes\n* Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of 0 to 1 at Screening\n* Has a life expectancy of more than 6 months\n* In addition to these general inclusion criteria, participants must meet all the module cohort-specific inclusion criteria\n\nInclusion Criteria ModA Part 1 Cohort Specific:\n\n* Pathologically confirmed diagnosis of solid cancer and documentation of Kirsten rat sarcoma (KRAS), Harvey rat sarcoma virus (HRAS), neuroblastoma ras viral oncogene homolog (NRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), v-raf murine sarcoma viral oncogene homolog C1(CRAF), and/or neurofibromatosis 1 (NF1) mutation\n* Have exhausted all available standard of care therapies that are known to provide benefit for the participant's condition, as judged by the Investigator\n\nInclusion Criteria ModA Part 2 Cohort Specific:\n\n* Documented BRAF gene mutation\n* Pathologically confirmed diagnosis with PD after at least one prior line of therapy in the advanced or metastatic setting\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "General Exclusion Criteria ModA Part 1 and 2:\n\n* Prior treatment with certain BRAF dimer inhibitors\n* Female participant is pregnant or lactating\n* Received any prior or concurrent medications or therapies known to be prohibited with DCC-3084 within 14 days\n* Received any prior antitumor therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-3084\n* Known allergy or hypersensitivity to any component of the study drug\n* Invasive malignancy within 2 years prior to the first dose of study drug other than the study indication or specific types of cancer treated with curative intent\n* Have not recovered from all clinically relevant toxicities from prior therapy\n* Impaired cardiac function\n* History of recent thrombotic or embolic events\n* Malabsorption syndrome or other illness that could affect oral absorption\n* Major surgery within 28 days of the first dose of study drug\n* In addition to the general exclusion criteria, participants will also be excluded based on the cohort-specific exclusion criteria\n\nExclusion Criteria: Module A Part 2 Cohort Specific:\n\n• Has known co-occurring mutation of KRAS, HRAS, NRAS, NF1, epidermal growth factor receptor, Phosphoinositide-3-kinase, catalytic, alpha polypeptide (PI3KCA), or Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Able to take oral medication",
            "criterions": [
                {
                    "exact_snippets": "Able to take oral medication",
                    "criterion": "ability to take oral medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements",
            "criterions": [
                {
                    "exact_snippets": "If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "all participants agree to follow the contraception requirements",
                    "criterion": "contraception requirements agreement",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function and electrolytes",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... electrolytes",
                    "criterion": "electrolytes",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of 0 to 1 at Screening",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of 0 to 1 at Screening",
                    "criterion": "Eastern Cooperative Oncology Group Performance Status (ECOG-PS)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a life expectancy of more than 6 months",
            "criterions": [
                {
                    "exact_snippets": "life expectancy of more than 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* In addition to these general inclusion criteria, participants must meet all the module cohort-specific inclusion criteria",
            "criterions": [
                {
                    "exact_snippets": "participants must meet all the module cohort-specific inclusion criteria",
                    "criterion": "module cohort-specific inclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pathologically confirmed diagnosis of solid cancer and documentation of Kirsten rat sarcoma (KRAS), Harvey rat sarcoma virus (HRAS), neuroblastoma ras viral oncogene homolog (NRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), v-raf murine sarcoma viral oncogene homolog C1(CRAF), and/or neurofibromatosis 1 (NF1) mutation",
            "criterions": [
                {
                    "exact_snippets": "Pathologically confirmed diagnosis of solid cancer",
                    "criterion": "solid cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "documentation of Kirsten rat sarcoma (KRAS), Harvey rat sarcoma virus (HRAS), neuroblastoma ras viral oncogene homolog (NRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), v-raf murine sarcoma viral oncogene homolog C1(CRAF), and/or neurofibromatosis 1 (NF1) mutation",
                    "criterion": "KRAS, HRAS, NRAS, BRAF, CRAF, or NF1 mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have exhausted all available standard of care therapies that are known to provide benefit for the participant's condition, as judged by the Investigator",
            "criterions": [
                {
                    "exact_snippets": "Have exhausted all available standard of care therapies that are known to provide benefit for the participant's condition",
                    "criterion": "standard of care therapies",
                    "requirements": [
                        {
                            "requirement_type": "exhaustion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "as judged by the Investigator",
                    "criterion": "investigator judgment",
                    "requirements": [
                        {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented BRAF gene mutation",
            "criterions": [
                {
                    "exact_snippets": "Documented BRAF gene mutation",
                    "criterion": "BRAF gene mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pathologically confirmed diagnosis with PD after at least one prior line of therapy in the advanced or metastatic setting",
            "criterions": [
                {
                    "exact_snippets": "Pathologically confirmed diagnosis",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathological"
                        }
                    ]
                },
                {
                    "exact_snippets": "PD",
                    "criterion": "progressive disease (PD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "after at least one prior line of therapy in the advanced or metastatic setting",
                    "criterion": "prior lines of therapy in the advanced or metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "disease setting",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Received any prior or concurrent medications or therapies known to be prohibited with DCC-3084 within 14 days",
            "criterions": [
                {
                    "exact_snippets": "Received any prior or concurrent medications or therapies known to be prohibited with DCC-3084 within 14 days",
                    "criterion": "use of medications or therapies prohibited with DCC-3084",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 28 days of the first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 28 days of the first dose of study drug",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "event timing",
                            "expected_value": "before first dose of study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Impaired cardiac function",
            "criterions": [
                {
                    "exact_snippets": "Impaired cardiac function",
                    "criterion": "cardiac function",
                    "requirements": [
                        {
                            "requirement_type": "impairment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received any prior antitumor therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-3084",
            "criterions": [
                {
                    "exact_snippets": "Received any prior antitumor therapy",
                    "criterion": "prior antitumor therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": "within a specified timeframe prior to first dose of DCC-3084"
                        }
                    ]
                },
                {
                    "exact_snippets": "any investigational therapy within a specified timeframe prior to first dose of DCC-3084",
                    "criterion": "investigational therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": "within a specified timeframe prior to first dose of DCC-3084"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of recent thrombotic or embolic events",
            "criterions": [
                {
                    "exact_snippets": "History of recent thrombotic or embolic events",
                    "criterion": "thrombotic or embolic events",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": "recent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with certain BRAF dimer inhibitors",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with certain BRAF dimer inhibitors",
                    "criterion": "prior treatment with BRAF dimer inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug type",
                            "expected_value": "certain BRAF dimer inhibitors"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have not recovered from all clinically relevant toxicities from prior therapy",
            "criterions": [
                {
                    "exact_snippets": "Have not recovered from all clinically relevant toxicities from prior therapy",
                    "criterion": "toxicities from prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical_relevance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female participant is pregnant or lactating",
            "criterions": [
                {
                    "exact_snippets": "Female participant is pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* In addition to the general exclusion criteria, participants will also be excluded based on the cohort-specific exclusion criteria",
            "criterions": [
                {
                    "exact_snippets": "general exclusion criteria",
                    "criterion": "general exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "adherence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cohort-specific exclusion criteria",
                    "criterion": "cohort-specific exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "adherence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Invasive malignancy within 2 years prior to the first dose of study drug other than the study indication or specific types of cancer treated with curative intent",
            "criterions": [
                {
                    "exact_snippets": "Invasive malignancy within 2 years prior to the first dose of study drug",
                    "criterion": "invasive malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years prior to the first dose of study drug"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "other than the study indication or specific types of cancer treated with curative intent",
                    "criterion": "type of malignancy",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "study indication",
                                "specific types of cancer treated with curative intent"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known allergy or hypersensitivity to any component of the study drug",
            "criterions": [
                {
                    "exact_snippets": "Known allergy or hypersensitivity to any component of the study drug",
                    "criterion": "allergy or hypersensitivity to study drug components",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Malabsorption syndrome or other illness that could affect oral absorption",
            "criterions": [
                {
                    "exact_snippets": "Malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other illness that could affect oral absorption",
                    "criterion": "illness affecting oral absorption",
                    "requirements": [
                        {
                            "requirement_type": "effect on oral absorption",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "• Has known co-occurring mutation of KRAS, HRAS, NRAS, NF1, epidermal growth factor receptor, Phosphoinositide-3-kinase, catalytic, alpha polypeptide (PI3KCA), or Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN)",
            "criterions": [
                {
                    "exact_snippets": "Has known co-occurring mutation of KRAS",
                    "criterion": "KRAS mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has known co-occurring mutation of ... HRAS",
                    "criterion": "HRAS mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has known co-occurring mutation of ... NRAS",
                    "criterion": "NRAS mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has known co-occurring mutation of ... NF1",
                    "criterion": "NF1 mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has known co-occurring mutation of ... epidermal growth factor receptor",
                    "criterion": "epidermal growth factor receptor mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has known co-occurring mutation of ... Phosphoinositide-3-kinase, catalytic, alpha polypeptide (PI3KCA)",
                    "criterion": "PI3KCA mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has known co-occurring mutation of ... Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN)",
                    "criterion": "PTEN mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "General Inclusion Criteria ModA Part 1 and 2:",
            "criterions": []
        },
        {
            "line": "Inclusion Criteria ModA Part 1 Cohort Specific:",
            "criterions": []
        },
        {
            "line": "Inclusion Criteria ModA Part 2 Cohort Specific:",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "Exclusion Criteria: Module A Part 2 Cohort Specific:",
            "criterions": []
        },
        {
            "line": "General Exclusion Criteria ModA Part 1 and 2:",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}